Enterprise value of top companies in non-oncology rare disease therapeutics 2017

Enterprise value of leading pure players in non-oncology rare disease therapeutics worldwide as of 2017 (in million U.S. dollars)*

by Matej Mikulic, last edited Nov 20, 2017
Enterprise value of top companies in non-oncology rare disease therapeutics 2017 This statistic shows the enterprise value of leading pure players in non-oncology rare disease therapeutics worldwide as of 2017. In 2017, the value of Biogen which manufactures especially multiple sclerosis therapeutics stood at nearly 70 billion U.S. dollars.
Show more

Enterprise value of leading pure players in non-oncology rare disease therapeutics worldwide as of 2017 (in million U.S. dollars)*

Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Pharmaceutical trends in Europe"
  • Overview
The most important statistics
  • European Pharmaceutical companies
  • Self-medication market
  • Employment
  • Clinical Trials
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.